Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Gallium 68 PSMA (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms ProsPERo
- 10 Jun 2017 Biomarkers information updated
- 22 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Jan 2017 Planned initiation date changed from 1 Sep 2016 to 1 Jun 2017.